A Rare T-Cell Leukemia Mutation Defies Expectations in a Four-Year Case
A rare form of leukemia has challenged assumptions about how a potentially important cancer-driving mutation behaves, according to a case report published in Annals of Hematology. Researchers describe a 58-year-old woman whose blood contained a persistent population of abnormal immune cells characteristic of T-large granular lymphocytic leukemia, or T-LGLL. The unusual cells carried a mutation in the STAT5B gene, a molecular alteration previously associated with aggressive disease in some forms of this disorder. Yet despite the mutation, the patient remained clinically well and required no treatment. Her condition stayed stable for more than four years, with no signs of progressive leukemia, organ enlargement, autoimmune disease or systemic inflammation. The observation does not overturn the broader evidence linking STAT5B to disease biology, but it shows that the mutation alone cannot reliably predict how every rare T-LGLL case will behave.
T-LGLL is an uncommon clonal lymphoproliferative disorder in which a genetically related population of cytotoxic T lymphocytes accumulates in the blood, bone marrow and sometimes other tissues. The word “clonal” is important: rather than representing a diverse collection of normal immune cells responding to infection, the abnormal population descends from a single altered precursor and carries a shared T-cell receptor rearrangement. Most T-LGLL cases arise from CD8-positive alpha-beta T cells, a major class of immune cells that recognize infected or abnormal cells and can destroy them. The case reported by Hee-Jeong Youk, Chan Jeoung Park, Mi Jung Park and Hee Ryeong Jang belongs to a much less common biological category. Its leukemia cells expressed a gamma-delta T-cell receptor, lacked both CD4 and CD8 surface proteins, and co-expressed the natural-killer-cell-associated markers CD16 and CD56.
The patient’s laboratory results revealed a substantial but remarkably stable abnormal population. Large granular lymphocytes accounted for approximately half of all leukocytes in peripheral blood, with an absolute concentration of 3.65 billion cells per liter. Large granular lymphocytes are named for the visible cytoplasmic granules that contain molecules used by cytotoxic immune cells to kill target cells. In the bone marrow, abnormal lymphocytes represented 11.2 percent of nucleated cells. Such findings can raise concern for a chronic lymphoid malignancy, but diagnosis depends on more than the cell count. Clinicians must establish that the population is persistent, immunophenotypically unusual and clonally related. In this case, the abnormal lymphocytes remained detectable for over four years, while serial complete blood counts showed no progressive leukocytosis. Hemoglobin and platelet concentrations also remained stable, suggesting that the abnormal clone was not progressively crowding out normal blood production.
Flow cytometry supplied the distinctive immunological fingerprint. This technique uses fluorescently labeled antibodies to measure proteins on the surface or inside individual cells as they pass through a laser beam. The patient’s abnormal cells displayed a gamma-delta T-cell receptor rather than the more common alpha-beta receptor. They were CD4-negative and CD8-negative, a configuration known as “double negative,” and also carried CD16 and CD56. CD4 and CD8 are co-receptors that help T cells interpret antigen-recognition signals, while CD16 and CD56 are often associated with natural killer cells and specialized cytotoxic lymphocyte subsets. A gamma-delta, double-negative phenotype therefore places these cells at an immunological crossroads, sharing features with several unconventional lymphocyte populations. Because this combination is rare in T-LGLL, it can complicate classification and raises questions about whether the cells originate through a distinct developmental pathway from conventional CD8-positive alpha-beta T-LGLL.
Molecular testing established that the abnormal cells were not merely an expanded response to an unidentified stimulus. Analysis of T-cell receptor gamma gene rearrangements demonstrated clonality, indicating that the lymphocytes were genetically related. Cytogenetic analysis found a normal karyotype, meaning that the conventional chromosome-level examination did not detect large gains, losses or rearrangements. The researchers then used targeted next-generation sequencing on DNA from the patient’s bone marrow. This approach reads selected genes at very high depth, allowing laboratories to identify mutations present in only a small fraction of cells. The analysis found a c.1883 C>G substitution in STAT5B, producing the amino-acid change T628S. The mutation had a variant allele frequency of 6.5 percent, indicating that mutant DNA represented a minority of the sequenced genetic material, consistent with the presence of a relatively small malignant clone within the entire marrow sample. The test also identified a CCND3 variant whose clinical significance could not be determined.
STAT5B encodes signal transducer and activator of transcription 5B, a transcription factor that helps convert external growth and survival signals into changes in gene activity. When cytokines or other signaling molecules bind to receptors on a lymphocyte, associated enzymes can phosphorylate STAT proteins. Activated STAT5B molecules pair up, enter the nucleus and influence genes involved in cell survival, proliferation, metabolism and immune-cell development. Mutations that alter this pathway may allow lymphocytes to receive or maintain survival signals abnormally, helping a clone persist. STAT5B alterations have been reported in subsets of T-LGLL and in other lymphoid malignancies, and some variants have been linked to more aggressive clinical features, depending on the disease context and the broader genetic background. The T628S substitution changes a threonine residue to serine at position 628. Although the two amino acids share some chemical properties, even a conservative substitution can affect protein regulation, phosphorylation or interactions with other signaling components. The precise functional impact of T628S remains unresolved.
That uncertainty is central to the new case. A mutation can be biologically relevant without acting as a simple on-or-off switch for aggressive cancer. Its effect may depend on where it occurs in the protein, how strongly it activates signaling, which other mutations accompany it, and which cell type carries it. The tissue environment and the patient’s immune system may also constrain the clone. In the reported patient, the STAT5B mutation appeared alongside an indolent clinical course rather than rapid progression. She had no B symptoms such as unexplained fever, drenching night sweats or weight loss. Doctors found no enlarged lymph nodes, enlarged liver or spleen, autoimmune disease or abnormal inflammatory markers. Her red-cell and platelet production remained steady, and the total white-cell count did not progressively rise. These observations indicate that the mutation’s presence should not automatically be interpreted as evidence that treatment is urgently required.
The case also highlights why rare leukemia subtypes are difficult to study. T-LGLL is uncommon overall, while gamma-delta and double-negative variants make up only a small fraction of cases. Most available molecular and clinical conclusions are therefore drawn from limited patient series rather than large prospective trials. A signal that appears strongly associated with aggressive behavior in one subtype may have a weaker or different meaning in another. Even within a single subtype, genetic alterations can occur at different allele frequencies and in different combinations. The CCND3 finding in this patient illustrates another challenge: sequencing frequently detects variants for which current evidence is insufficient to determine whether they promote disease, merely accompany it or have no meaningful effect. As genomic testing becomes more sensitive, clinicians will increasingly need to distinguish actionable drivers from incidental or uncertain findings.
For now, the report supports careful long-term monitoring rather than mutation-based predictions in isolation. The patient remained untreated because her blood counts and clinical condition were stable, but the absence of progression in one individual does not prove that every T-LGLL carrying STAT5B T628S will follow the same course. Nor does it establish that the mutation is harmless; it may still contribute to the survival or persistence of the abnormal lymphocyte population. The finding instead adds a crucial nuance to the biology of T-LGLL: molecular risk markers must be interpreted alongside cell phenotype, clone size, symptoms, blood-count trends, organ involvement and the pace of change over time. Larger studies of gamma-delta, CD4-negative/CD8-negative T-LGLL will be needed to determine whether this mutation defines a reproducible subgroup or represents an unusual event in an otherwise rare disease. Until then, the case serves as a vivid reminder that cancer genetics can reveal what a disease is capable of, but not always what it will do next.
Subject of Research: A rare indolent gamma-delta, CD4-negative/CD8-negative double-negative T-large granular lymphocytic leukemia carrying a STAT5B T628S mutation
Subject of Research: Cancer
Article Title: Indolent γδ CD4−/CD8− double negative T-large granular lymphocytic leukemia with a STAT5B T628S mutation: a case report
Article References: Indolent γδ CD4−/CD8− double negative T-large granular lymphocytic leukemia with a STAT5B T628S mutation: a case report — Springer Nature, Annals of Hematology
Image Credits: AI Generated
DOI: 10.1007/s00277-026-07256-x
Keywords: T-large granular lymphocytic leukemia, gamma-delta T cells, double-negative T cells, STAT5B mutation, T628S, clonal lymphoproliferative disorder, indolent leukemia, next-generation sequencing
Tags: atypical disease progression in T-LGLLautoimmune features and T-LGLLautoimmune features associated with T-LGLLgenetic markers in T-cell leukemiaimmune cell abnormalities in lymphoproliferative disordersimmune cell clonality in T-LGLLimpact of STAT5B mutations on leukemia prognosisindolent T-LGLL case reportindolent T-LGLL case studylonglong-term stability in T-LGLL with mutationmolecular genetics of indolent lymphmolecular genetics of T-LGLLrare T-cell lymphoproliferative disorderrole of genetic mutations in leukemia behaviorstable disease despite oncogenic mutationsSTAT5B mutation in T-cell leukemiaSTAT5B T628S mutation clinical implicationsSTAT5B T628S mutation clinical significanceT-cell lymphoproliferative disordersT-large granular lymphocytic leukemia
